Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
In an interim analysis of a phase 3 clinical trial conducted in the UK, the vaccine has shown 89% efficacy, with 27% of participants in the trial – almost 4,000 people – older than 65. That trial suggested 95.6% efficacy against the original coronavirus and 85.6% efficacy against the more recent UK strain. Those results were based on the first 62 cases of Covid-19 identified among volunteers, with 56 cases among those given a placebo against just six in those given the vaccine.
The poorest countries are missing out on adequate doses of vaccines – and the health implications should concern us all
Nine months ago world leaders were queueing up to declare any Covid-19 vaccine a global public good. Today we are witness to a vaccine apartheid that is only serving the interests of powerful and profitable pharmaceutical corporations while costing us the quickest and least harmful route out of this crisis.
I am sickened by news that South Africa, a country whose HIV history should have taught us all the most appalling life-costing consequences of allowing pharmaceutical corporations to protect their medicine monopolies, has had to pay more than double the price paid by the European Union for the AstraZeneca vaccine for far fewer doses than it actually needs. Like so many other low- and middle-income countries, South Africa is today facing a vaccine landscape of depleted supply where it is purchasing power, not suffering, that will secure the few remaining doses.
An international team of World Health Organization experts has emerged from quarantine in the Chinese city of Wuhan, to begin much-delayed fieldwork into the origins of the Sars-CoV-2 virus that caused the Covid-19 pandemic.
The fact-finding mission has been beset by controversy after the WHO accused China of dragging its heels over arrangements. The team arrived more than a year after doctors in the city first raised the alarm about a mystery new illness spreading among their patients.
German authorities have advised that the Oxford/AstraZeneca jab should not be given to those aged 65 or above. We take a look at why, and what experts make of it.
Why has Germany advised the Oxford/AstraZeneca jab should only be used in adults under 65?
Scientists are studying the similarities between long Covid and ongoing symptoms experienced by survivors of Ebola and Chikungunya virus in the hope of devising new treatments to improve their health.
Like patients with long Covid, survivors of these other, relatively new human viruses, often experience lingering symptoms which can make it difficult to work or function in everyday life.
While CSL told the Committee it was too busy to appear, other major companies, including Pfizer and AstraZeneca, have appeared. Pfizer appeared despite currently trying to meet a tight deadline of delivering its vaccine for roll-out in Australia by the end of the month.
It is totally disrespectful for CSL, the recipient of $1.7 billion in taxpayer funded vaccine related contracts, to refuse to appear before today’s Senate COVID Committee. If they won’t respect the Senate’s request, they should expect a ‘subpoena’. #auspolhttps://t.co/ZS3gMO8VoE
CSL appreciates invitation to attend the Senate Select Committee Hearing on COVID-19. Due to our commitment to urgently deliver 50 million doses of a safe and effective COVID-19 vaccine we are unable to resource our participation at this time.
In response to the global pandemic, CSL employees allocated to the COVID-19 vaccine program are fully focussed and working around the clock to ensure vaccines are available for use in Australia as soon as possible. We will be in a better position to consider a similar invitation later in the year.
Virgin Australia has cut another 350 jobs, this time at its head office in Brisbane, the Australian Services Union says.
It comes on top of more than 3000 sackings at the airline since it was bought by US investment group Bain Capital last year after going into administration due to the coronavirus crisis.
Joe Biden’s administration demands ‘robust and clear’ investigation as WHO team visits Wuhan
The US wants a “robust and clear” international probe into the origins of the Covid-19 pandemic in China, the White House press secretary, Jen Psaki, has said.
Speaking to reporters, she said it was “imperative we get to the bottom” of how the virus appeared and spread. She highlighted “great concern” over “misinformation” from “some sources in China”.
Patel said too many people are coming in and out of the country every day, but told MPs on Wednesday more details will be set out by the health department next week.
Firstly, the police have stepped up checks and are carrying out more physical checks at addresses to ensure that people are complying with the self-isolation rules.
Second, we will continue to refuse entry to non-UK residents from red-list countries which are already subject to the UK travel ban.
The European Union health commissioner has said that AstraZeneca has committed to providing the bloc with doses from four plants, including two in Britain, Reuters reports.
Stella Kyriakides told a news conference that the company had legal obligations to comply with the contract.
Relatives of Wuhan’s coronavirus dead have said Chinese authorities deleted their social media group and told them to keep quiet while a World Health Organization team was in the city preparing to begin an investigation into the pandemic’s origins.
Scores of people had banded together online in a shared quest for accountability from the Wuhan officials they blame for mishandling the Covid-19 outbreak that tore through the city a year ago, and caused more than 4,000 officially recorded deaths there.
The German government is expected to announce tighter border controls after warnings from leading virologists that the move is vital to control the spread in the country of more contagious variants of Covid-19.
Angela Merkel, the chancellor, is widely reported to have told a meeting of her CDU party colleagues that air travel in particular needed to be restricted “to the extent that you simply can’t get anywhere any more”.
Yesterday Britain passed a grim milestone. A further 1,631 deaths from Covid-19 were recorded, taking the official tally above 100,000, though data from the Office for National Statistics suggests the total number will now be nearer 120,000. In a briefing, Boris Johnson has said his government did everything it could to minimise the loss of life, but these deaths were far from inevitable. While the number of UK deaths has entered the hundreds of thousands, New Zealand has recorded only 25 deaths from Covid-19 so far. Taiwan has recorded seven, Australia 909, Finland 655, Norway 550 and Singapore 29. These countries have largely returned to normal daily life.
In the first year of the pandemic, the UK faced three big challenges. Our national government had no long-term strategy for suppressing the virus beyond a continual cycle of lockdowns. Even now we still don’t know what the government’s plans for the next six months are. In the early days of the pandemic, the UK treated Covid-19 like a bad flu. The government halted testing, and the initial plan seemed to be allow the virus to run unchecked through the population (the “herd immunity” approach). Finally, ministers have pitted the economy against public health, instead of realising that the health of the economy depends upon a healthy population.
AstraZeneca’s chief executive has insisted the UK will come first for vaccines as he rejected calls to divert doses to the European Union following a breakdown in supply.
Amid a growing row, Pascal Soriot, the French head of the pharmaceutical giant, said the UK was benefiting from being early to sign a contract for 100m doses.
The Oxford/AstraZeneca vaccine may be authorised only for younger people in Europe, because there is insufficient data on how well it works in the over-65s, the head of the regulatory body has suggested.
The European Medicines Agency (EMA) is expected to authorise the AstraZeneca vaccine at the end of this week, a month after it was approved in the UK.
Analysis: technical problem at Belgium plant failed to produce enough vaccine but EU demanding fulfilment of contract
AstraZeneca warned the European commission on Friday that there would be a significant shortfall in the promised 100m vaccine doses this quarter, of up to 60%. It says this is due to a technical issue: not enough vaccine is being produced by the main plant making the supplies destined for Europe, which is in Belgium.
A row has broken out after German newspapers suggested the Oxford/AstraZeneca vaccine might have a lower efficacy among the over-65s. Below we take a look at the claims, and whether we should be concerned.
The EU “means business”, Ursula von der Leyen has said, as the bloc doubled down on plans for tighter monitoring of vaccine exports to countries outside of the union, such as the UK.
Speaking at the World Economic Forum, the president of the European commission said the EU had invested billions and “companies must now deliver” to the 27 member states.
Ten of the world’s most infectious diseases identified by the WHO not being catered for by drug firms
The world’s biggest pharmaceutical firms are little prepared for the next pandemic despite a mounting response to the Covid-19 outbreak, an independent report has warned.
Jayasree K Iyer, executive director of the Netherlands-based Access to Medicine Foundation, a not-for-profit organisation funded by the UK and Dutch governments and others, highlighted an outbreak of the Nipah virus in China, with a fatality rate of up to 75%, as potentially the next big pandemic risk.
One in eight people who have had Covid-19 are diagnosed with their first psychiatric or neurological illness within six months of testing positive for the virus, a new analysis suggests, adding heft to an emerging body of evidence that stresses the toll of the virus on mental health and brain disorders cannot be ignored.
The analysis – which is still to be peer-reviewed – also found that those figures rose to one in three when patients with a previous history of psychiatric or neurological illnesses were included.
Exactly a year after his first story about coronavirus, our science editor received the Pfizer injection last week. Here he reflects on a remarkable scientific achievement
I marked a grim anniversary in an unexpected manner last week. On 18 January last year, I wrote my first story about a mysterious disease that had struck Wuhan, in China, and which was now spreading around the world. More than two million individuals have since died of Covid-19, almost 100,000 of them in the UK.
Remarkably, 12 months to the day that the Observer published my story, I was given my first dose of Covid-19 vaccine, allowing me to follow nearly six million other newly immunised UK residents who are set to gain protection against a disease that has brought the planet to a standstill. It was a rare, comforting experience after a year of unremitting sadness and gloom.